2016
DOI: 10.1016/j.nmd.2016.05.014
|View full text |Cite
|
Sign up to set email alerts
|

213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18–20 September 2015

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
14
0
1

Year Published

2017
2017
2024
2024

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 20 publications
(15 citation statements)
references
References 94 publications
0
14
0
1
Order By: Relevance
“…However, there was no correlation between the mapping parameters and Troponin‐T, CK levels, or duration of the disease, which might be a result of the patient sample size. Meanwhile, it has been shown that the use of simple laboratory data to measure disease activity and outcomes is not appropriate in this patient population . For decades, the Disease Activity Core Set Measures developed by the International Clinical Assessment and Studies Group (IMACS) for IIM have been widely used, and these measures have also been used as clinical outcomes for IIM .…”
Section: Discussionmentioning
confidence: 99%
“…However, there was no correlation between the mapping parameters and Troponin‐T, CK levels, or duration of the disease, which might be a result of the patient sample size. Meanwhile, it has been shown that the use of simple laboratory data to measure disease activity and outcomes is not appropriate in this patient population . For decades, the Disease Activity Core Set Measures developed by the International Clinical Assessment and Studies Group (IMACS) for IIM have been widely used, and these measures have also been used as clinical outcomes for IIM .…”
Section: Discussionmentioning
confidence: 99%
“…One limitation of this study might be the use of the SF‐12 rather than the SF‐36 for the assessment of HRQoL. The SF‐36 is the recommended HRQoL assessment tool and patient‐reported outcome measure for the evaluation of response to therapy in myositis by the International Myositis Assessment and Clinical Studies Group . Indeed, the SF‐12 has been used in only a few studies of HRQoL in IIM , which makes comparisons of results from this study to others more difficult.…”
Section: Discussionmentioning
confidence: 99%
“…However, there are few sizable studies assessing HRQoL in patients with IIM . Due to the rarity of these conditions, previous studies had small sample sizes, which prohibited adequately powered statistical comparisons to delineate patient or IIM factors associated with HRQoL outcomes .…”
Section: Introductionmentioning
confidence: 99%
“…Un siècle plus tard les myopathies auto-immunes sont regroupées dans deux cadres nosologiques : celui de la polymyosite et celui de la dermatomyosite [2]. Aujourd'hui, de nombreux sous-groupes de myopathies inflammatoires ont été identifiés, grâce à des définitions histologiques plus précises, d'une part [3], et grâce à l'apport des auto-anticorps spécifiques des myosites, d'autre part. Il est important de souligner que quelle que soit la classification utilisée (histologique ou sérologique), les définitions reposent toujours sur atteinte musculaire bilatérale et diffuse.…”
Section: Introductionunclassified